Streetbeat News

Price Targets

CIEN

Raymond James analyst Simon Leopold maintains a Strong Buy rating on Ciena (NYSE:CIEN) but lowers the price target from $70 to $63.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 7:59 am

ABNB

Needham analyst Bernie McTernan reiterated a Buy rating on Airbnb (NASDAQ:ABNB) and maintained a $150 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 7:58 am

GIII

Keybanc analyst Noah Zatzkin maintains an Overweight rating on G-III Apparel Group (NASDAQ:GIII) and raises the price target from $18 to $23.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 7:57 am

AMED

In the last 3 months, 12 analysts have provided 12-month price targets for Amedisys (NASDAQ:AMED), with an average price target of $100.0, a 6.1% decrease from the previous average of $106.50. The ratings include 4 bullish, 8 indifferent, and no bearish ratings.

Portfolio Pulse from Benzinga Insights

June 06, 2023 | 8:01 pm

KLAC

A large investor has taken a bullish stance on KLA Corporation (NASDAQ:KLAC), with 11 uncommon options trades spotted, 54% bullish and 45% bearish. Whales have been targeting a price range of $185 to $490 for KLA over the last 3 months. Wells Fargo maintains an Overweight rating with a $500 price target, while UBS maintains a Neutral rating with a $475 price target.

Portfolio Pulse from Benzinga Insights

June 06, 2023 | 8:01 pm

TEAM

A large bearish position on Atlassian (NASDAQ: TEAM) has been spotted, with 60% of big-money traders showing bearish sentiment. Whales have been targeting a price range of $180 to $250 for Atlassian over the last 3 months. Wells Fargo maintains an Overweight rating with a $200 price target, while Barclays maintains an Equal-Weight rating with a $130 price target.

Portfolio Pulse from Benzinga Insights

June 06, 2023 | 7:46 pm

ERAS

Erasca's stock is trading lower after the company decided to discontinue its ERAS-007 programs, leading multiple firms to lower their price targets.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 7:33 pm

CSTL

Canaccord Genuity maintains a Buy rating on Castle Biosciences Inc (NASDAQ:CSTL) but lowers the price target from $60 to $40 due to lower DecisionDxSCC revenue and an increased discount rate. Novitas has stated that Castle's DecisionDx-SCC and DecisionDx-Melanoma do not meet the criteria for coverage, but the company is working on a solution.

Portfolio Pulse from Vandana Singh

June 06, 2023 | 7:28 pm

NVRO

Nevro Corp shares are trading lower after multiple firms lowered their respective price targets for the company.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 7:25 pm

LII

KeyBanc Capital Markets analyst Jeffrey D. Hammond upgraded Lennox International Inc (NYSE:LII) from Sector Weight to Overweight with a price target of $355. The analyst expects LII's initiatives to boost utilization in its distribution footprint and drive higher non-equipment sales, leading to increased profitability. Hammond also sees potential for factory efficiency improvements in LII's Commercial HVAC business.

Portfolio Pulse from Lekha Gupta

June 06, 2023 | 7:06 pm